Pretransplant administration of interleukin-25 (IL-25) protected goblet cells from GVHD, prevented bacterial translocation, reduced IFN-γ and IL-6 plasma levels, and ameliorated GVHD. This evidence concerns the gene IFNG and graft versus host disease.